| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Included within cash and cash equivalents | 40,463 | 42,271 | ||
| Marketable securities | 23 | 17 | ||
| Accounts receivable | 127 | 256 | ||
| Prepaid expenses and other current assets | 1,647 | 1,300 | ||
| Total current assets | 42,260 | 43,844 | ||
| Property and equipment, net | 2,157 | 2,255 | ||
| Operating lease right-of-use assets | 2,311 | 1,817 | ||
| Deposits and other long-term assets | 539 | 511 | ||
| Goodwill | 10,672 | 10,672 | ||
| Intangible assets, net | 31,700 | 31,700 | ||
| Total assets | 89,639 | 90,799 | ||
| Accounts payable and accrued liabilities | 4,550 | 4,451 | ||
| Operating lease liabilities, current portion | 1,023 | 998 | ||
| Finance lease liabilities, current portion | 43 | 50 | ||
| Deferred revenues, current portion | 3,766 | 5,257 | ||
| Total current liabilities | 9,382 | 10,756 | ||
| Deferred tax liability | 273 | 273 | ||
| Deferred revenues, net of current portion | 12,462 | 12,751 | ||
| Operating lease liabilities, net of current portion | 1,515 | 1,058 | ||
| Finance lease liabilities, net of current portion | 40 | 48 | ||
| Warrant liabilities | 45,171 | 18,801 | ||
| Preferred shares, no par value, 2,000 shares authorized none issued and outstanding as of june 30, 2025 and december 31, 2024 | - | 0 | ||
| Total liabilities | 68,843 | 43,687 | ||
| Common shares, no par value, 450,000 shares authorized as of september 30, 2025 and december 31, 2024 230,328 and 220,416 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 494,175 | 490,551 | ||
| Accumulated other comprehensive loss | -4,286 | -4,098 | ||
| Accumulated deficit | -467,849 | -438,068 | ||
| Lineage's shareholders' equity | 22,040 | 48,385 | ||
| Noncontrolling deficit | -1,244 | -1,273 | ||
| Total shareholders equity | 20,796 | 47,112 | ||
| Total liabilities and shareholders equity | 89,639 | 90,799 | ||
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)